TXN1をターゲットにすることで,P38 MAPK経路を通じてグリオマ細胞のG2M相停止とアポトーシスを誘導する
Lu Zhou1, Hongsheng Liang2, Chenyi Nie1
1Northeast Agricultural University, Harbin, 150000, China.
Applied biochemistry and biotechnology
|August 20, 2025
まとめ
膠原腫細胞におけるTXN1の抑制はASK1/ P38 MAPK経路を活性化し,細胞サイクル停止とアポトーシスを引き起こします. この発見は,膠原腫患者の予後を改善するための潜在的な治療戦略を提供します.
科学分野:
- 腫瘍学
- 分子生物学
- 細胞生物学
背景:
- 膠原腫は,細胞の反アポトーシスによる化学放射線治療後の予後が悪い,攻撃的な脳腫瘍です.
- 分子メカニズムをターゲットにすることが 有効なグリオマ治療に不可欠です
研究 の 目的:
- 細胞増殖とアポトーシスにおけるTXN1の役割を調査する.
- TXN1が影響する分子経路を明らかにする.
主な方法:
- TXN1発現の生物情報学予測と臨床組織検証
- レンチウイルス媒介のTXN1抑制を用いたインビトロ研究.
- 細胞サイクル,アポトーシス,およびMTT,フローサイトメトリー,免疫光,ウェスタンブロット,およびqRT-PCRによるP38MAPK経路活性分析.
- 裸のマウスのクセノ移植と免疫ヒストケミストリーのインビボ研究
主要な成果:
- TXN1の発現は悪性結晶腫と患者さんの予後不良と相関しています.
- TXN1を抑制すると,G2 / M細胞サイクル停止とアポトーシスの増加が生じます.
- TXN1の減少はASK1/ P38MAPK経路を活性化させ,ミトコンドリア損傷を引き起こした.
- TXN1の抑制により,膠原細胞におけるアポプトシス抵抗が逆転した.
結論:
- TXN1の阻害はASK1/ P38MAPK経路を活性化し,膠原細胞サイクル停止とアポトーシスを誘導する.
- TXN1をターゲットにすることで,悪性結晶腫の化学抵抗を克服する有望な戦略を示しています.
- TXN1阻害剤との併用療法により,膠原腫患者の臨床結果が改善される可能性があります.
関連する概念動画
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
The Intrinsic Apoptotic Pathway
6.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K


